Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | flavodoxin family protein | 0.008 | 0.29 | 0.29 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.008 | 0.29 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0049 | 0.1436 | 0.1436 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.0066 | 0.2242 | 0.7729 |
Trichomonas vaginalis | NADPH cytochrome P450, putative | 0.003 | 0.0536 | 0.1849 |
Trypanosoma brucei | S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase, putative | 0.003 | 0.0536 | 0.1849 |
Echinococcus multilocularis | methionine synthase reductase | 0.0049 | 0.1436 | 0.4951 |
Loa Loa (eye worm) | hypothetical protein | 0.0066 | 0.2242 | 0.2242 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.008 | 0.29 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.008 | 0.29 | 0.29 |
Loa Loa (eye worm) | follicle stimulating hormone receptor | 0.0227 | 1 | 1 |
Trypanosoma cruzi | Flavodoxin/Radical SAM superfamily/Wyosine base formation, putative | 0.003 | 0.0536 | 0.1849 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.008 | 0.29 | 1 |
Echinococcus multilocularis | acetylcholinesterase | 0.0066 | 0.2242 | 0.7729 |
Plasmodium vivax | flavodoxin domain containing protein | 0.0071 | 0.2465 | 0.8159 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0019 | 0 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.008 | 0.29 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.003 | 0.0536 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.008 | 0.29 | 1 |
Loa Loa (eye worm) | carboxylesterase | 0.0066 | 0.2242 | 0.2242 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.004 | 0.0972 | 0.5 |
Leishmania major | p450 reductase, putative | 0.008 | 0.29 | 1 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0071 | 0.2465 | 1 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.008 | 0.29 | 1 |
Entamoeba histolytica | type A flavoprotein, putative | 0.003 | 0.0536 | 1 |
Trypanosoma cruzi | NADPH--cytochrome P450 reductase, putative | 0.003 | 0.0536 | 0.1849 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.008 | 0.29 | 1 |
Trypanosoma cruzi | Flavodoxin/Radical SAM superfamily/Wyosine base formation, putative | 0.003 | 0.0536 | 0.1849 |
Schistosoma mansoni | cytochrome P450 reductase | 0.008 | 0.29 | 1 |
Echinococcus granulosus | acetylcholinesterase | 0.0066 | 0.2242 | 0.7729 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.008 | 0.29 | 1 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.0071 | 0.2465 | 0.8499 |
Giardia lamblia | Hypothetical protein | 0.0071 | 0.2465 | 1 |
Echinococcus granulosus | carboxylesterase 5A | 0.0066 | 0.2242 | 0.7729 |
Echinococcus multilocularis | carboxylesterase 5A | 0.0066 | 0.2242 | 0.7729 |
Brugia malayi | FAD binding domain containing protein | 0.008 | 0.29 | 0.29 |
Treponema pallidum | flavodoxin | 0.003 | 0.0536 | 0.5 |
Brugia malayi | Carboxylesterase family protein | 0.0066 | 0.2242 | 0.2242 |
Echinococcus granulosus | methionine synthase reductase | 0.0049 | 0.1436 | 0.4951 |
Entamoeba histolytica | type A flavoprotein, putative | 0.003 | 0.0536 | 1 |
Leishmania major | hypothetical protein, conserved | 0.003 | 0.0536 | 0.1849 |
Trichomonas vaginalis | NADPH cytochrome P450, putative | 0.003 | 0.0536 | 0.1849 |
Loa Loa (eye worm) | hypothetical protein | 0.008 | 0.29 | 0.29 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.004 | 0.1001 | 0.345 |
Entamoeba histolytica | type A flavoprotein, putative | 0.003 | 0.0536 | 1 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.0019 | 0 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.008 | 0.29 | 1 |
Chlamydia trachomatis | sulfite reductase | 0.0049 | 0.1436 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.008 | 0.29 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.008 | 0.29 | 1 |
Loa Loa (eye worm) | flavodoxin family protein | 0.003 | 0.0536 | 0.0536 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.008 | 0.29 | 1 |
Echinococcus multilocularis | acetylcholinesterase | 0.0066 | 0.2242 | 0.7729 |
Echinococcus granulosus | acetylcholinesterase | 0.0066 | 0.2242 | 0.7729 |
Trichomonas vaginalis | sulfite reductase, putative | 0.008 | 0.29 | 1 |
Schistosoma mansoni | diflavin oxidoreductase | 0.004 | 0.0972 | 0.335 |
Entamoeba histolytica | type A flavoprotein, putative | 0.003 | 0.0536 | 1 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.0066 | 0.2242 | 0.2242 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.008 | 0.29 | 1 |
Brugia malayi | Carboxylesterase family protein | 0.0066 | 0.2242 | 0.2242 |
Brugia malayi | FAD binding domain containing protein | 0.0049 | 0.1436 | 0.1436 |
Loa Loa (eye worm) | hypothetical protein | 0.0066 | 0.2242 | 0.2242 |
Trypanosoma cruzi | p450 reductase, putative | 0.008 | 0.29 | 1 |
Trichomonas vaginalis | NADPH cytochrome P450, putative | 0.003 | 0.0536 | 0.1849 |
Leishmania major | cytochrome P450 reductase, putative | 0.0071 | 0.2465 | 0.8499 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.004 | 0.0972 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.008 | 0.29 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.008 | 0.29 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0049 | 0.1436 | 0.4951 |
Brugia malayi | flavodoxin family protein | 0.003 | 0.0536 | 0.0536 |
Trichomonas vaginalis | NADPH cytochrome P450, putative | 0.003 | 0.0536 | 0.1849 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.